Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma
Novartis drug Afinitor is first treatment for advanced pancreatic NET to provide overall survival of more than 3.5 years in Phase III trial
Patients lived average of 18 months without cancer progressing when taking Novartis' Zykadia(TM) as their first ALK inhibitor for ALK+ NSCLC
Roche's investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone
Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Presentation of Phase 3 Results for a PD-1 Immune Checkpoint Inhibitor
Boehringer Ingelheim's afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer
GENENTECH'S PERJETA REGIMEN EXTENDED THE LIVES OF PEOPLE WITH AN AGGRESSIVE TYPE OF METASTATIC BREAST CANCER BY 15.7 MONTHS COMPARED TO HERCEPTIN AND CHEMOTHERAPY
ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer
BASEL, Switzerland, Sept.
Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics
Editor Note: For more information about this release, please scroll to bottom.
LONDON, September 26, 2014
Abbott Completes Acquisition of CFR Pharmaceuticals; Announces Results of Tender Offer for CFR Shares
Acquisition enhances Abbott's position in Latin America, more than doubling its branded generics pharmaceutical sales and presence in the fast-growing region